Skandinaviska Enskilda Banken AB publ Sells 26,232 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Skandinaviska Enskilda Banken AB publ cut its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 12.0% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 191,515 shares of the company’s stock after selling 26,232 shares during the period. Skandinaviska Enskilda Banken AB publ owned approximately 0.67% of Krystal Biotech worth $35,170,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Jamison Private Wealth Management Inc. bought a new stake in Krystal Biotech in the 2nd quarter valued at about $28,000. GAMMA Investing LLC increased its position in Krystal Biotech by 160.3% in the 2nd quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock valued at $28,000 after buying an additional 93 shares in the last quarter. Key Financial Inc bought a new stake in Krystal Biotech in the 2nd quarter valued at about $28,000. Blue Trust Inc. increased its position in Krystal Biotech by 2,328.6% in the 2nd quarter. Blue Trust Inc. now owns 170 shares of the company’s stock valued at $30,000 after buying an additional 163 shares in the last quarter. Finally, Quest Partners LLC bought a new stake in Krystal Biotech in the 2nd quarter valued at about $71,000. 86.29% of the stock is owned by institutional investors.

Insider Transactions at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total value of $4,944,000.00. Following the transaction, the insider now owns 1,500,882 shares in the company, valued at approximately $296,814,424.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 14.10% of the company’s stock.

Krystal Biotech Stock Up 1.0 %

Shares of NASDAQ KRYS opened at $184.48 on Friday. Krystal Biotech, Inc. has a twelve month low of $93.95 and a twelve month high of $219.34. The stock’s 50 day moving average price is $195.52 and its 200-day moving average price is $179.21. The company has a market capitalization of $5.27 billion, a PE ratio of 98.65 and a beta of 0.82.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, August 5th. The company reported $0.53 earnings per share for the quarter, topping analysts’ consensus estimates of $0.50 by $0.03. Krystal Biotech had a return on equity of 1.99% and a net margin of 63.73%. The firm had revenue of $70.28 million for the quarter, compared to the consensus estimate of $65.27 million. During the same quarter in the previous year, the business earned ($1.25) EPS. The company’s revenue was up 70283900.0% compared to the same quarter last year. As a group, research analysts expect that Krystal Biotech, Inc. will post 3.13 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently commented on KRYS shares. William Blair raised Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. Citigroup reissued a “neutral” rating and set a $204.00 price objective (up from $195.00) on shares of Krystal Biotech in a report on Tuesday, August 6th. HC Wainwright boosted their price objective on Krystal Biotech from $200.00 to $221.00 and gave the stock a “buy” rating in a report on Wednesday, August 28th. Chardan Capital boosted their price objective on Krystal Biotech from $153.00 to $208.00 and gave the stock a “buy” rating in a report on Monday, August 5th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $196.75.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).